Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2009 | 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Accounts receivable | -256,000 | -1,032,000 | -717,000 | -470,000 | -502,000 |
| Other Working Capital | 1,129,000 | -210,000 | -443,000 | 108,000 | 332,000 |
| Other Operating Activity | 10,866,000 | 9,984,000 | 8,670,000 | 8,055,000 | 6,913,000 |
| Operating Cash Flow | $11,739,000 | $8,742,000 | $7,510,000 | $7,693,000 | $6,743,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -2,195,000 | -4,001,000 | -1,625,000 | -643,000 | -723,000 |
| Net Acquisitions | 0 | N/A | -14,891,000 | -1,148,000 | N/A |
| Purchase Of Investment | -31,000 | -40,000 | -35,000 | -17,000 | -503,000 |
| Sale Of Investment | 3,000 | 33,000 | 1,315,000 | 1,188,000 | N/A |
| Purchase Sale Intangibles | -355,000 | N/A | N/A | N/A | N/A |
| Other Investing Activity | 371,000 | 112,000 | 349,000 | 348,000 | 44,000 |
| Investing Cash Flow | $-2,476,000 | $-3,896,000 | $-14,887,000 | $-272,000 | $-1,182,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -137,000 | N/A | N/A | N/A | N/A |
| Debt Repayment | -650,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | 135,000 | 159,000 | 218,000 | 985,000 | 143,000 |
| Common Stock Repurchased | 0 | -610,000 | -4,170,000 | -4,147,000 | -3,001,000 |
| Dividend Paid | -2,977,000 | -2,739,000 | -2,641,000 | -2,220,000 | -1,717,000 |
| Other Financing Activity | 0 | -3,172,000 | 12,644,000 | 16,000 | 3,000 |
| Financing Cash Flow | $-3,629,000 | $-6,362,000 | $6,051,000 | $-5,366,000 | $-4,572,000 |
| Exchange Rate Effect | 71,000 | -88,000 | 64,000 | 39,000 | -21,000 |
| Beginning Cash Position | 4,123,000 | 5,727,000 | 6,989,000 | 4,895,000 | 3,927,000 |
| End Cash Position | 9,828,000 | 4,123,000 | 5,727,000 | 6,989,000 | 4,895,000 |
| Net Cash Flow | $5,634,000 | $-1,516,000 | $-1,326,000 | $2,055,000 | $989,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 11,739,000 | 8,742,000 | 7,510,000 | 7,693,000 | 6,743,000 |
| Capital Expenditure | -2,957,000 | -4,039,000 | -1,679,000 | -1,339,000 | -810,000 |
| Free Cash Flow | 8,782,000 | 4,703,000 | 5,831,000 | 6,354,000 | 5,933,000 |